Treating nosocomial pneumonia: what s new #MMPMID29978856
Frantzeskaki F; Orfanos SE
ERJ Open Res 2018[Apr]; 4 (2): ä PMID29978856show ga
Nosocomial pneumonia is an infection of lung parenchyma that occurs in patients hospitalised for more than 48?h after admission [1]. Hospital-acquired pneumonia (HAP) is nosocomial pneumonia in patients who do not require mechanical ventilation; while ventilator-associated pneumonia (VAP) is defined as a pneumonia developing in patients under mechanical ventilation for at least 48?h [2]. HAP is the second most common nosocomial infection, and is the most common hospital infection leading to death in critically ill patients [1]. VAP is the most frequent hospital-acquired infection in intensive care units. Depending on the diagnostic criteria used, its incidence ranges from 5% to 67% [3]. The risk of acquiring VAP is 3% per day during the first 5?days on mechanical ventilation, and it is decreased to 1% per day for the following days. HAP or VAP developing within 4?days of admission are defined as early HAP/VAP, and are usually caused by microorganisms sensitive to antibiotics. HAP or VAP occurring after 5?days of admission are defined as late-onset pneumonias, and are most commonly associated with multidrug-resistant (MDR) pathogens [4, 5]. The mortality of late-onset VAP is higher than the respective mortality for early-onset VAP [6]. The crude mortality of nosocomial pneumonia is estimated to reach 70%. Attributable mortality, which is defined as the percentage of deaths that would have been prevented in the absence of infection, is 10% [7].
free
free
free
ERJ+Open+Res 2018 ; 4 (2): ä
